CL2017001180A1 - Dianhidrogalactitol en conjunto con radiación para tratar carcinoma de células no pequeñas del pulmón y glioblastoma multiforme - Google Patents
Dianhidrogalactitol en conjunto con radiación para tratar carcinoma de células no pequeñas del pulmón y glioblastoma multiformeInfo
- Publication number
- CL2017001180A1 CL2017001180A1 CL2017001180A CL2017001180A CL2017001180A1 CL 2017001180 A1 CL2017001180 A1 CL 2017001180A1 CL 2017001180 A CL2017001180 A CL 2017001180A CL 2017001180 A CL2017001180 A CL 2017001180A CL 2017001180 A1 CL2017001180 A1 CL 2017001180A1
- Authority
- CL
- Chile
- Prior art keywords
- dianhydrogalactitol
- lung
- radiation
- conjunction
- small cell
- Prior art date
Links
- AAFJXZWCNVJTMK-GUCUJZIJSA-N (1s,2r)-1-[(2s)-oxiran-2-yl]-2-[(2r)-oxiran-2-yl]ethane-1,2-diol Chemical compound C([C@@H]1[C@H](O)[C@H](O)[C@H]2OC2)O1 AAFJXZWCNVJTMK-GUCUJZIJSA-N 0.000 title abstract 4
- 229950000758 dianhydrogalactitol Drugs 0.000 title abstract 4
- 208000005017 glioblastoma Diseases 0.000 title abstract 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 title abstract 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 title 1
- 230000005855 radiation Effects 0.000 title 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 102100025825 Methylated-DNA-protein-cysteine methyltransferase Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 201000005296 lung carcinoma Diseases 0.000 abstract 1
- 108040008770 methylated-DNA-[protein]-cysteine S-methyltransferase activity proteins Proteins 0.000 abstract 1
- 230000011987 methylation Effects 0.000 abstract 1
- 238000007069 methylation reaction Methods 0.000 abstract 1
- 230000008263 repair mechanism Effects 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 229960004964 temozolomide Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Radiation-Therapy Devices (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
<p>EL USO DE DIANHIDROGALACTITOL PROPORCIONA UNA NUEVA MODALIDAD TERAPÉUTICA PARA EL TRATAMIENTO DE CARCINOMA DE PULMÓN DE CÉLULAS NO PEQUEÑAS (NSCLC) Y PARA EL TRATAMIENTO DE GLIOBLASTOMA MULTIFORME (GBM). EL DIANHIDROGALACTITOL ACTÚA COMO UN AGENTE ALQUILANTE EN EL ADN QUE CREA UNA METILACIÓN EN N7. EL DIANHIDROGALACTITOL ES EFECTIVO EN LA SUPRESIÓN DEL CRECIMIENTO DE LAS CÉLULAS MADRE CANCEROSAS Y ES ACTIVO CONTRA LOS TUMORES QUE SON REFRACTARIOS A LA TEMOZOLOMIDA; EL FÁRMACO ACTÚA INDEPENDIENTEMENTE DEL MECANISMO DE REPARACIÓN DE MGMT.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462077712P | 2014-11-10 | 2014-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017001180A1 true CL2017001180A1 (es) | 2017-12-29 |
Family
ID=55954912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017001180A CL2017001180A1 (es) | 2014-11-10 | 2017-05-10 | Dianhidrogalactitol en conjunto con radiación para tratar carcinoma de células no pequeñas del pulmón y glioblastoma multiforme |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190015379A1 (es) |
| EP (1) | EP3217970A4 (es) |
| JP (3) | JP2017536356A (es) |
| KR (2) | KR20170081261A (es) |
| CN (2) | CN107231794A (es) |
| AU (1) | AU2015346598B2 (es) |
| BR (1) | BR112017009845A2 (es) |
| CA (1) | CA2967322A1 (es) |
| CL (1) | CL2017001180A1 (es) |
| IL (1) | IL252192B2 (es) |
| MX (1) | MX2017006076A (es) |
| SG (1) | SG11201703810QA (es) |
| TW (1) | TW201632181A (es) |
| WO (1) | WO2016077264A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190015379A1 (en) * | 2014-11-10 | 2019-01-17 | Delmar Pharmaceuticals, Inc. | Use of dianhydrogalactitol and analogs and derivatives thereof, together with radiation, to treat non-small-cell carcinoma of the lung and glioblastoma multiforme and suppress proliferation of cancer stem cells |
| WO2018204412A1 (en) * | 2017-05-01 | 2018-11-08 | Thomas Jefferson University | Systems-level analysis of tcga cancers reveals disease trna fragmentation patterns and associations with messenger rnas and repeat |
| CN111164104A (zh) | 2017-08-09 | 2020-05-15 | 麻省理工学院 | 白蛋白结合肽缀合物及其方法 |
| CN109512833B (zh) * | 2018-12-04 | 2020-10-30 | 天津医科大学总医院 | E2f6抑制剂的功能与用途 |
| WO2021207650A1 (en) * | 2020-04-09 | 2021-10-14 | L.E.A.F. Holdings Group Llc | Trans-crocetin compositions and treatment regimens |
| KR102560912B1 (ko) * | 2020-08-26 | 2023-07-28 | 한양대학교 에리카산학협력단 | 엑소좀을 유효성분으로 포함하는 폐암 치료, 예방 또는 전이 억제용 약학적 조성물 |
| CN113599524B (zh) * | 2021-09-02 | 2023-05-02 | 中国医学科学院肿瘤医院 | Hnrnpc和rbmx作为靶点在制备治疗小细胞肺癌的产品中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4938949A (en) * | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| KR20130088908A (ko) * | 2008-06-17 | 2013-08-08 | 와이어쓰 엘엘씨 | Ｈｋｉ-272 및 비노렐빈을 함유하는 항신생물성 조합물 |
| US9066918B2 (en) * | 2010-08-18 | 2015-06-30 | Del Mar Pharmaceuticals | Methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol |
| KR20220137154A (ko) * | 2012-01-20 | 2022-10-11 | 데니스 엠. 브라운 | 다형교모세포종 및 수모세포종을 비롯한 신생종양 질환 및 암 줄기세포의 치료를 위한 디안히드로갈락티톨 및 유사체를 비롯한 치환된 헥시톨의 용도 |
| KR102359214B1 (ko) * | 2014-04-04 | 2022-02-07 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
| US20190015379A1 (en) * | 2014-11-10 | 2019-01-17 | Delmar Pharmaceuticals, Inc. | Use of dianhydrogalactitol and analogs and derivatives thereof, together with radiation, to treat non-small-cell carcinoma of the lung and glioblastoma multiforme and suppress proliferation of cancer stem cells |
-
2015
- 2015-11-10 US US15/525,933 patent/US20190015379A1/en not_active Abandoned
- 2015-11-10 CA CA2967322A patent/CA2967322A1/en active Pending
- 2015-11-10 KR KR1020177015926A patent/KR20170081261A/ko not_active Application Discontinuation
- 2015-11-10 CN CN201580071196.6A patent/CN107231794A/zh active Pending
- 2015-11-10 MX MX2017006076A patent/MX2017006076A/es unknown
- 2015-11-10 KR KR1020227046292A patent/KR20230008252A/ko not_active Application Discontinuation
- 2015-11-10 AU AU2015346598A patent/AU2015346598B2/en active Active
- 2015-11-10 IL IL252192A patent/IL252192B2/en unknown
- 2015-11-10 TW TW104136993A patent/TW201632181A/zh unknown
- 2015-11-10 EP EP15858948.1A patent/EP3217970A4/en active Pending
- 2015-11-10 BR BR112017009845A patent/BR112017009845A2/pt not_active Application Discontinuation
- 2015-11-10 CN CN202211009952.0A patent/CN115414480A/zh active Pending
- 2015-11-10 JP JP2017525080A patent/JP2017536356A/ja active Pending
- 2015-11-10 WO PCT/US2015/059814 patent/WO2016077264A1/en active Application Filing
- 2015-11-10 SG SG11201703810QA patent/SG11201703810QA/en unknown
-
2017
- 2017-05-10 CL CL2017001180A patent/CL2017001180A1/es unknown
-
2020
- 2020-07-30 JP JP2020129093A patent/JP2020183445A/ja active Pending
-
2022
- 2022-09-08 JP JP2022142672A patent/JP2022174200A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022174200A (ja) | 2022-11-22 |
| WO2016077264A1 (en) | 2016-05-19 |
| SG11201703810QA (en) | 2017-06-29 |
| KR20170081261A (ko) | 2017-07-11 |
| BR112017009845A2 (pt) | 2018-01-16 |
| IL252192A0 (en) | 2017-07-31 |
| KR20230008252A (ko) | 2023-01-13 |
| CN115414480A (zh) | 2022-12-02 |
| MX2017006076A (es) | 2017-12-11 |
| JP2020183445A (ja) | 2020-11-12 |
| EP3217970A4 (en) | 2018-07-18 |
| IL252192B2 (en) | 2024-03-01 |
| JP2017536356A (ja) | 2017-12-07 |
| CA2967322A1 (en) | 2016-05-19 |
| TW201632181A (zh) | 2016-09-16 |
| IL252192B1 (en) | 2023-11-01 |
| US20190015379A1 (en) | 2019-01-17 |
| AU2015346598B2 (en) | 2020-09-03 |
| CN107231794A (zh) | 2017-10-03 |
| EP3217970A1 (en) | 2017-09-20 |
| AU2015346598A1 (en) | 2017-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017001180A1 (es) | Dianhidrogalactitol en conjunto con radiación para tratar carcinoma de células no pequeñas del pulmón y glioblastoma multiforme | |
| BR112014017833A8 (pt) | Uso de hexitóis substituídos incluindo dianidrogalactitol e análogos para tratar doença neoplástica e células-tronco de câncer incluindo glioblastoma multiforme e meduloblastoma | |
| CL2016002312A1 (es) | Modulador del receptor de andrógeno y usos de este. | |
| MX2021004828A (es) | Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia. | |
| CL2018000706A1 (es) | Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer. | |
| GT201500294A (es) | Compuestos de biaril-amida como inhibidores de cinasa | |
| PH12018502731A1 (en) | Treatment of cancer with dihydropyrazino-pyrazines | |
| PE20150223A1 (es) | Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos | |
| AR091220A1 (es) | Metodos para tratar cancer usando antagonistas de union a pd-1 axis y antagonistas de vegf | |
| NZ716033A (en) | Treatment of papulopustular rosacea with ivermectin | |
| BR112015023439A2 (pt) | combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki | |
| MX2015011671A (es) | Co-administracion de esteroides y acido zoledronico para prevenir y tratar la osteoartritis. | |
| MX2018000052A (es) | Composiciones y métodos para la terapia combinada con virus del dengue y celulas dendríticas. | |
| CO6761366A2 (es) | Composiciones farmacéuticas para el tratamiento de glioma maligno | |
| NZ730195A (en) | Heterocyclic compounds and use thereof | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| TW201612313A (en) | Uses of ligustilide | |
| EP2964237A4 (en) | METHOD FOR STORING THE POPULATION OF THERAPEUTIC CELLS AT THE TREATMENT CENTER OF A PERSON FOR CELL THERAPY | |
| AR105142A1 (es) | Métodos de tratamiento del glioblastoma multiforme con terapia de células t | |
| SV2016005308A (es) | Composiciã“n farmacã‰utica para el tratamiento de alopatã�as relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol | |
| TW201613599A (en) | Use of composition for manufacture of medicament for suppressing androgen receptor related function and treatment of androgen receptor related disease | |
| MX2018008196A (es) | Tratamiento para cancer de mama usando una combinacion de una formulacion liposomal cationica de taxano, una formulacion no liposomal de taxano y un agente activo adicional. | |
| GB2527477A (en) | Tumour Therapy | |
| AR105601A1 (es) | Formulaciones y usos para suministro de micropartículas de metaloporfirinas |